Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Gynecologic Oncology

Expertise Matters: Building Your Rare Ovarian Cancer Care Team

At a Glance

For rare ovarian cancer, assembling a specialized multidisciplinary care team at a high-volume cancer center is crucial. This team should include a gynecologic oncologist and a subspecialized pathologist to ensure an accurate diagnosis and access to cutting-edge clinical trials.

When you have a rare ovarian cancer, your most important “treatment” isn’t a drug—it’s the team of experts you assemble. Because rare subtypes behave so differently from common ovarian cancer, being treated at a high-volume, specialized center (often a National Cancer Institute (NCI)-designated center) is associated with significantly better outcomes and more accurate diagnoses [1][2][3].

The Multidisciplinary Team (MDT)

Rare cancers require a “brain trust” of specialists who look at your case from every angle. A true multidisciplinary team for rare ovarian cancer should include:

  • Gynecologic Oncologist: A surgeon and cancer specialist who coordinates your overall care. They are specifically trained to perform the precise surgeries required for ovarian cancers [4].
  • Subspecialized Pathologist: This is critical. A general pathologist may see your rare tumor once a year, but a specialist sees them daily, reducing the high risk of misdiagnosis in rare subtypes [5][6].
  • Medical Oncologist: Especially one with expertise in targeted therapies (like MEK inhibitors) or hormonal treatments, rather than just standard chemotherapy [4][7].
  • Genetic Counselor: Essential for identifying rare hereditary links that could affect your treatment and your family’s health. For example, DICER1 mutations are linked to certain sex cord-stromal tumors [8][9], and Lynch Syndrome is frequently linked to endometriosis-associated tumors like Clear Cell carcinoma [10][11].

Why Specialized Centers Matter

In rare disease, “volume” equals “expertise.” High-volume centers are more likely to follow the latest evidence-based guidelines, such as utilizing fertility-sparing surgery for young patients with germ cell or sex cord tumors [12][3]. They also have access to Molecular Tumor Boards, where experts review your tumor’s DNA to find “actionable” targets that standard tests might miss [13][14].

Accessing Rare Disease Clinical Trials

For many rare ovarian cancers, the best treatment option is often a clinical trial, as standard-of-care options for recurrent disease can be limited [15][16]. Modern “precision medicine” trials are designed specifically for rare diseases:

  • Basket and Umbrella Trials: These innovative designs (like the BOUQUET or RAMP studies) group patients by their tumor’s genetic mutations rather than just where the cancer started [13][17].
  • Histology-Specific Trials: Some trials focus solely on one rare type, such as the RAMP 301 study (NCT06072781) for recurrent Low-Grade Serous Ovarian Cancer (LGSOC) or the HI-MOC study (NCT05123807) for Mucinous Ovarian Cancer [18][19].
  • Where to Look: Use specific terms like “Clear Cell Ovarian” or “Sex Cord-Stromal” when searching databases like ClinicalTrials.gov, rather than just “Ovarian Cancer,” which will mostly return results for the common high-grade type [18][19].

Building your team at a center that actively participates in these trials ensures you aren’t just getting the “standard” treatment, but the one that is most likely to work for your unique biology [20][21]. As you progress through treatment, this team will also guide you through your Long-Term Survivorship and Follow-Up.

Common questions in this guide

Why do I need a subspecialized pathologist for rare ovarian cancer?
A subspecialized pathologist sees rare tumors daily, which significantly reduces the risk of misdiagnosis. General pathologists may only encounter these specific rare cancer subtypes once a year, making expert review essential for an accurate diagnosis.
What doctors should be on my ovarian cancer care team?
A multidisciplinary team is a 'brain trust' of experts who review your case from different medical perspectives. For rare ovarian cancers, this essential group typically includes a gynecologic oncologist, a medical oncologist, a specialized pathologist, and a genetic counselor.
Should I travel to a specialized center for my rare ovarian cancer treatment?
Traveling to a high-volume or National Cancer Institute (NCI)-designated center is highly recommended if your local hospital has limited experience. Treating rare subtypes at specialized centers is associated with more accurate diagnoses, access to trials, and significantly better outcomes.
What is a molecular tumor board?
A molecular tumor board is a group of experts at specialized centers who review the specific DNA mutations of your tumor. They look for 'actionable' genetic targets to match you with modern precision treatments that standard tests might miss.
How do I find clinical trials for rare ovarian cancer?
You can search databases like ClinicalTrials.gov using your specific tumor type, such as 'Clear Cell Ovarian' or 'Low-Grade Serous,' rather than just 'Ovarian Cancer.' Treating at a high-volume center also gives you better access to specialized basket and umbrella trials.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many patients with my exact histological subtype have you treated in the last year?
  2. 2.Is there a specialized gynecologic pathologist on-site who will review my slides, or can we send them to a major cancer center for a second opinion?
  3. 3.Does this hospital have a multidisciplinary tumor board that includes specialists in rare gynecologic cancers?
  4. 4.Are there any 'basket' or 'precision medicine' clinical trials available here that match my tumor's molecular mutations?
  5. 5.Who is the primary point of contact (e.g., a nurse navigator) who can help coordinate between different specialists on my team?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    A Comprehensive Review of Current Trends in the Diagnosis and Treatment of Ovarian Germ Cell Tumors.

    Dantkale KS, Agrawal M

    Cureus 2024; (16(1)):e52650 doi:10.7759/cureus.52650.

    PMID: 38380211
  2. 2

    Mixed ovarian germ cell tumor in a child: A case report of a rare association.

    Benradi L, El Haissoufi K, Ammor A, et al.

    Annals of medicine and surgery (2012) 2021; (65()):102237 doi:10.1016/j.amsu.2021.102237.

    PMID: 33898029
  3. 3

    ESGO-SIOPE guidelines for the management of adolescents and young adults with non-epithelial ovarian cancers.

    Sessa C, Schneider DT, Planchamp F, et al.

    The Lancet. Oncology 2020; (21(7)):e360-e368 doi:10.1016/S1470-2045(20)30091-7.

    PMID: 32615119
  4. 4

    A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review).

    Falzone L, Scandurra G, Lombardo V, et al.

    International journal of oncology 2021; (59(1)).

    PMID: 34132354
  5. 5

    Fertility-Sparing Surgery and Adjuvant Chemotherapy with Trastuzumab Result in Complete Remission in a Young Woman with Rare Primary Mucinous Ovarian Cancer due to ERBB2 Co-amplification with CDK12 and Chromosome 11q13.3 Amplicon: A Case Report and Literature Review.

    Gao L, Huang T, Zhong L, et al.

    Reproductive sciences (Thousand Oaks, Calif.) 2024; (31(6)):1626-1631 doi:10.1007/s43032-023-01443-1.

    PMID: 38216775
  6. 6

    Rare ovarian tumors: an update on diagnosis and treatment.

    Debuquoy C, Romeo C, Vanacker H, Ray-Coquard I

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2020; (30(6)):879-887 doi:10.1136/ijgc-2020-001235.

    PMID: 32461259
  7. 7

    Low-grade Serous Tumors: Are We Making Progress?

    Pauly N, Ehmann S, Ricciardi E, et al.

    Current oncology reports 2020; (22(1)):8 doi:10.1007/s11912-020-0872-5.

    PMID: 31989304
  8. 8

    Changing patterns of referrals and outcomes of genetic participation in gynaecological-oncology multidisciplinary care.

    Pokharel HP, Hacker NF, Andrews L

    The Australian & New Zealand journal of obstetrics & gynaecology 2016; (56(6)):633-638 doi:10.1111/ajo.12504.

    PMID: 27530527
  9. 9

    Recurrent gynandroblastoma of the ovary with germline DICER1 mutation: A case report and review of the literature.

    Mercier AM, Zorn KK, Quick CM, Huffman LB

    Gynecologic oncology reports 2021; (37()):100806 doi:10.1016/j.gore.2021.100806.

    PMID: 34169133
  10. 10

    Aggressive Serous Carcinomas of the Female Reproductive Tract: Cancer-Prone Cell States and Genetic Drivers.

    Phuong DJ, Pirtz MG, Ralston CQ, et al.

    Cancers 2025; (17(4)) doi:10.3390/cancers17040604.

    PMID: 40002199
  11. 11

    The unique metabolome of clear cell ovarian carcinoma.

    Ji JX, Hoang LN, Cochrane DR, et al.

    The Journal of pathology 2024; (264(2)):160-173 doi:10.1002/path.6329.

    PMID: 39096103
  12. 12

    Reproductive Outcomes and Fertility Preservation Strategies in Women with Malignant Ovarian Germ Cell Tumors after Fertility Sparing Surgery.

    Vasta FM, Dellino M, Bergamini A, et al.

    Biomedicines 2020; (8(12)) doi:10.3390/biomedicines8120554.

    PMID: 33265938
  13. 13

    [Treatments for rare ovarian tumors: What's new?]

    Lebreton C, Quesada S, Bini M, et al.

    Bulletin du cancer 2023; (110(7-8)):818-824 doi:10.1016/j.bulcan.2023.03.007.

    PMID: 37045734
  14. 14

    Update on new treatments for rare ovarian tumours.

    Quesada S, Bini M, Lebreton C, Ray-Coquard I

    Current opinion in obstetrics & gynecology 2023; (35(1)):27-33 doi:10.1097/GCO.0000000000000836.

    PMID: 36440753
  15. 15

    Primary mucinous ovarian cancer: options for surgery and chemotherapy.

    Kurnit KC, Frumovitz M

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2022; (32(11)):1455-1462 doi:10.1136/ijgc-2022-003806.

    PMID: 36229081
  16. 16

    Predicting Long-Term Prognoses and Grading Platinum Sensitivity Using a Novel Progression-Free Interval Criterion in Ovarian Clear Cell Carcinoma: A Multi-Institutional Cohort Study.

    Chou CY, Cheng WF, Chen MY, et al.

    Cancers 2022; (14(7)) doi:10.3390/cancers14071746.

    PMID: 35406519
  17. 17

    The highs and lows of serous ovarian cancer.

    Grisham RN, Manning-Geist BL, Chui MH

    Cancer 2023; (129(17)):2613-2620 doi:10.1002/cncr.34903.

    PMID: 37366225
  18. 18

    Clearer Horizons: The latest advances in clear cell ovarian cancer treatment.

    Blanc-Durand F, Ngoi N, Lim D, et al.

    Cancer treatment reviews 2025; (138()):102977 doi:10.1016/j.ctrv.2025.102977.

    PMID: 40517636
  19. 19

    Targeting RAS-RAF-MEK-ERK signaling in mucinous ovarian cancer: a translational evidence synthesis and clinical framework.

    Bartl T, Cacsire Castillo-Tong D

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2026; (36(4)):104485 doi:10.1016/j.ijgc.2026.104485.

    PMID: 41680018
  20. 20

    Response to trametinib in recurrent low-grade serous ovarian cancer with NRAS mutation: A case report.

    Champer M, Miller D, Kuo DY

    Gynecologic oncology reports 2019; (28()):26-28 doi:10.1016/j.gore.2019.01.007.

    PMID: 30809568
  21. 21

    Investigating a clinically actionable BRAF mutation for monitoring low-grade serous ovarian cancer: A case report.

    Silva R, Moran B, Das S, et al.

    Case reports in women's health 2022; (34()):e00395 doi:10.1016/j.crwh.2022.e00395.

    PMID: 35198414

This page provides educational information about assembling a care team for rare ovarian cancer. Always consult a gynecologic oncologist or specialized cancer center for personalized medical advice regarding your specific diagnosis and treatment.

Get notified when new evidence is published on Rare ovarian cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.